Has Ahmed Mohamed received payments from drug or device companies?

Yes. Drug and device makers reported $4,567 in general payments to Ahmed Mohamed across 171 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Ahmed Mohamed did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Ahmed Mohamed come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Ahmed Mohamed

Cardiovascular Disease · Worcester, MANPI 1134571417

Payments from drug & device makers

What this record shows

This record is dominated by food and beverage: $3,983 of the $4,567 with a category attached, or 87.2%. It is spread thinly across 20 manufacturers, the largest accounting for just 21.1% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2024 at $1,867 and has fallen 77.2% since, to $425 in 2025.

$4,567in general payments, 2019–2025

Across 171 payments — averaging $26.71 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Amgen$964
ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$659
AstraZeneca$497
Shockwave Medical, Inc$341
Novartis$311
Abiomed$268
plus $2K from 14 others

What the payments were for

Food & beverage$3,98387%
Education$58513%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Amgen	42	$964
ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)	27	$659
AstraZeneca	24	$497
Shockwave Medical, Inc	2	$341
Novartis	17	$311
Abiomed	4	$268
Pfizer	12	$263
Abbott	1	$238
E.r. Squibb & Sons, L.L.C.	9	$202
Boehringer Ingelheim	9	$201
Actelion Pharmaceuticals US, Inc.	2	$142
Johnson & Johnson	3	$109
Scpharmaceuticals Inc.	5	$99
Kiniksa Pharmaceuticals International, PLC	5	$88
Cvrx, Inc.	2	$44
Alnylam Pharmaceuticals Inc.	2	$39
Boston Scientific	1	$35
Bridgebio Pharma, Inc.	2	$29
Eisai Inc.	1	$25
Novo Nordisk	1	$14

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

Shockwave IVL System with the Shockwave C2 Coronary IVL Catheter$341
ENSITE$238
UPTRAVI$115
OPSUMIT$115

How this compares

$4,567 in reported general payments places this provider in the 65th percentile of 750 cardiovascular disease providers in Massachusetts.

See all cardiovascular disease providers in Massachusetts →

Other cardiovascular disease in Worcester

Bryon Gentile IiWorcester$235K
Marc SabatineBoston$3.9M
Elizabeth NabelBoston$2.2M
Kenneth RosenfieldBoston$1.4M
Kevin CroceChestnut Hill$1.4M
James JanuzziBoston$1.1M
Muthiah VaduganathanBoston$972K
Joseph LoscalzoBoston$926K
Sunil KapurBoston$823K
Paul ZeiBoston$786K

See the full list for Massachusetts →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →